Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

Subtitle:Embracing nuclear medicine for the benefit of personalized immunotherapy

Molecular imaging of the immune checkpoint receptor PD-1 and its ligand PD-L1 is increasingly investigated as a strategy to guide and monitor PD-1:PD-L1-targeted immune checkpoint therapy. We provide an overview of the current state-of-the-art on PD-1- and PD-L1-specific imaging agents for quantitative, real-time assessment of PD-1:PD-L1 expression in the tumor environment and discuss their potential for clinical translation.

Publication year:2018

Keywords:Biomarker, Immunotherapy, Molecular imaging, PD-1:PD-L1

BOF-keylabel:yes

BOF-publication weight:6

CSS-citation score:3

Authors:International

Authors from:Higher Education

Accessibility:Open